Why the study?
Does MIDCAB surgery with LIMA to LAD grafting restore long-term survival in patients with ischaemic heart disease to that of an age-matched normal population?
Does MIDCAB surgery with LIMA to LAD grafting restore long-term survival in patients with ischaemic heart disease to that of an age-matched normal population?
MIDCAB surgery (LIMA to LAD grafting) provides excellent 20-year survival for selected patients with ischemic heart disease, matching the survival of the general population.
Supports excellent 20-year survival with MIDCAB in selected patients; leaves open confirmation by randomized trials.
MIDCAB is a safe and effective revascularization strategy which can be successfully performed in a carefully selected patient population with low morbidity and excellent long-term results. The survival of MIDCAB patients returns to that of their age/gender/year-matched counterparts within the normal population and hence should be offered as an alternative to coronary stenting when counselling patients with ischaemic heart disease.
No takes yet. Share an insight, caveat, or question.
Manuel et al. (2022) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: